文献速递脑血管病外科神经重症

治疗时机对动脉瘤性蛛网膜下腔出血患者脑梗死风险的影响

Impact of Treatment Timing on the Risk of Cerebral Infarction in Patients with Aneurysmal Subarachnoid Hemorrhage.
PubMed 文献 · World Neurosurg · 2022-09-28

本研究纳入2003年1月至2016年6月在本机构连续治疗的943例动脉瘤性蛛网膜下腔出血患者,其中111例在血管痉挛期(发病后第4-14天)接受治疗。倾向性评分匹配和多因素分析显示,血管痉挛期治疗与需动脉内痉挛缓解的血管痉挛、治疗血管远端脑梗死及6个月预后不良风险升高独立相关。

要点

  • 血管痉挛期(第4-14天)治疗与需动脉内痉挛缓解的血管痉挛风险升高相关(aOR 3.62)。
  • 血管痉挛期治疗与治疗动脉瘤远端脑梗死风险升高相关(aOR 2.02)。
  • 血管痉挛期治疗与6个月预后不良(改良Rankin量表评分>2)风险升高相关(aOR 2.05)。

核心结论

  • 本研究数据证实,在动脉瘤性蛛网膜下腔出血后第4天至第14天期间进行动脉瘤治疗,脑梗死和预后不良的风险相当高。
  • 对于在血管痉挛期进行动脉瘤治疗的患者,可能需要更密集的监测和脑血管痉挛的预防性治疗。

研究设计与样本

  • 本研究为单中心连续病例队列研究,纳入2003年1月至2016年6月在本机构治疗的动脉瘤性蛛网膜下腔出血患者。
  • 队列按治疗时机分为两组:血管痉挛期(发病后第4-14天)治疗组和超出血管痉挛期治疗组。
  • 统计分析包括1:1倾向性评分匹配分析和全队列多因素logistic回归分析。

主要发现

  • 943例动脉瘤性蛛网膜下腔出血患者中,111例在血管痉挛期接受治疗。
  • 倾向性评分匹配分析显示,血管痉挛期治疗患者需动脉内痉挛缓解的血管痉挛风险更高(P < 0.0001),治疗血管远端脑梗死风险更高(P < 0.0001),6个月随访预后不良(改良Rankin量表评分>2)风险更高(P = 0.025)。
  • 多因素分析显示,血管痉挛期动脉瘤治疗与需动脉内痉挛缓解的脑血管痉挛风险升高独立相关(P < 0.0001;校正比值比[aOR] 3.62)。
  • 多因素分析显示,血管痉挛期动脉瘤治疗与治疗动脉瘤远端脑梗死风险升高独立相关(P = 0.01;aOR 2.02)。
  • 多因素分析显示,血管痉挛期动脉瘤治疗与预后不良风险升高独立相关(P = 0.03;aOR 2.05)。

临床怎么用

  • 作者认为,对于在血管痉挛期进行动脉瘤治疗的患者,可能需要更密集的监测和脑血管痉挛的预防性治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cerebral infarction is a major contributor to poor outcome in patients with aneurysmal subarachnoid hemorrhage (aSAH). Timing of treatment has been discussed as a possible contributor. We aimed to analyze the impact of treatment timing on the risk of cerebral infarction and poor outcome after aSAH. METHODS: Consecutive cases of patients with aSAH treated at our institution between January 2003 and June 2016 were included. The cohort was divided into 2 groups, depending on the treatment during (day 4-14 after ictus) or beyond the vasospasm phase. Statistical assessment included a 1:1 propensity score matching analysis and multivariable logistic regression analysis within the whole cohort. RESULTS: Of 943 patients with aSAH, 111 underwent treatment in the vasospasm phase. In the propensity score matching analysis, patients treated during the vasospasm phase were at higher risk of vasospasm requiring intra-arterial spasmolysis (P < 0.0001), cerebral infarction distal to the treated vessel (P < 0.0001), and poor outcome (modified Rankin Scale score >2) at 6 months follow-up (P = 0.025). In the multivariable analysis, aneurysm treatment in the vasospasm phase was independently associated with higher risk of cerebral vasospasm necessitating intra-arterial spasmolysis (P < 0.0001; adjusted odds ratio [aOR], 3.62), cerebral infarction distal to the treated aneurysm (P = 0.01; aOR, 2.02), and poor outcome (P = 0.03; aOR, 2.05). CONCLUSIONS: Our data confirm a considerable risk of cerebral infarction and poor outcome in cases of aneurysm treatment between day 4 and 14 after aSAH. A more intense surveillance and prophylactic treatment of cerebral vasospasm might be necessary in cases of aneurysm treatment in the vasospasm phase.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Santos AN, Nii-Amon-Kotei DN, Dinger TF, et al. Impact of Treatment Timing on the Risk of Cerebral Infarction in Patients with Aneurysmal Subarachnoid Hemorrhage. World Neurosurg. 2022. PMID: 36182063. doi:10.1016/j.wneu.2022.09.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。